These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11875991)

  • 21. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
    Thijssen HH; Verkooijen IW; Frank HL
    Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
    [No Abstract]   [Full Text] [Related]  

  • 22. Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
    Steward DJ; Haining RL; Henne KR; Davis G; Rushmore TH; Trager WF; Rettie AE
    Pharmacogenetics; 1997 Oct; 7(5):361-7. PubMed ID: 9352571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
    Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
    Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations of the CYP2C9 gene and the response to warfarin.
    Yasar U; Oscarson M; Eliasson E; Sjöqvist F
    Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
    [No Abstract]   [Full Text] [Related]  

  • 28. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
    Redman AR
    Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
    Taube J; Halsall D; Baglin T
    Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
    Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
    Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.
    Goldstein JA
    Br J Clin Pharmacol; 2002 Apr; 53(4):409-10. PubMed ID: 11966681
    [No Abstract]   [Full Text] [Related]  

  • 32. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
    Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.
    Rettie AE; Haining RL; Bajpai M; Levy RH
    Epilepsy Res; 1999 Jul; 35(3):253-5. PubMed ID: 10413320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
    London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
    Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic control of anticoagulation.
    Mannucci PM
    Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
    [No Abstract]   [Full Text] [Related]  

  • 36. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
    Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
    Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.
    Henne KR; Gaedigk A; Gupta G; Leeder JS; Rettie AE
    J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):143-8. PubMed ID: 9686881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
    Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
    Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of CYP2C9 polymorphism in losartan oxidation.
    Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
    Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.